摘要
目的探讨人类白细胞相关抗原DRB1*15(HLA-DRB1*15)等位基因位点与阿德福韦酯治疗慢性乙型肝炎(CHB)6个月时疗效的相关性。方法以阿德福韦酯治疗的CHB患者6个月时有效及无效病例(分别为52和42例)作为研究对象,采用序列特异性引物聚合酶链反应技术(PCR-SSP)对两组研究对象中HLA-DRB1*15基因位点进行检测并对此等位基因位点的频率进行比较分析。结果 HLA-DRB1*15等位基因位点在CHB及相同抗病毒疗效中分布与HBeAg无统计学差异,HLA-DRB1*15等位基因位点在治疗有效组和无效组中的频率分布差异存在统计学意义(χ2=5.050,P=0.025,OR=3.176,95%CI:1.127～8.951)。结论 HLA-DRB1*15在CHB及相同抗病毒疗效中的分布与HBeAg无相关性,HLA-DRB1*15可能是阿德福韦酯抗HBV有效的预测指标。
Objective To investigate the relationship between HLA-DRB1＊15 allele and the efficacy of adefovir dipivoxil in chronic hepatitis B for six months.Methods 94 chronic hepatitis B patients treated with adefovir dipivoxil were selected and divided into 52 cases of effective group and 42 cases of ineffective group.HLA-DRB1＊15 was detected by using the polymerase chain reaction sequence specific primer（PCR-SSP）,and the Frequencies of HLA-DRB1＊15 were analyzed between the two groups.Results No significant difference was found in HLA-DRB1＊15 frequency with hepatitis e antigen in chronic hepatitis B or in the same antiviral effect group.The frequency of HLA-DRB1＊15 in effective group was significantly higher than that in ineffective group（χ2=5.050,P=0.025,OR=3.176,95%CI：1.127 ~8.951）.Conclusion HLA-DRB1＊15 allele in chronic hepatitis B or in the same antiviral effect group has no relationship distribution with hepatitis e antigen.HLA-DRB1＊15 might be an effective treatment predictor marker of adefovir dipivoxil.
出处
《临床肝胆病杂志》
CAS
2012年第5期356-358,371,共4页
Journal of Clinical Hepatology
关键词
人类白细胞抗原
阿德福韦酯
肝炎
乙型
慢性
human leukocyte antigens
adefovir dipivoxil
hepatitis B
chronic
